Skip Navigation

Cardiovascular Research 2004 63(4):611-616; doi:10.1016/j.cardiores.2004.06.019
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smith, R. M.
Right arrow Articles by Sack, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, R. M.
Right arrow Articles by Sack, M. N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning

Robert M. Smitha,*,1, Naushaad Sulemana, Lydia Lacerdaa, Lionel H. Opiea, Shizuo Akirab, Kenneth R. Chienc and Michael N. Sackd

aHatter Institute for Cardiology Research, Faculty of Health Sciences, University of Cape Town Observatory, Cape Heart Centre, Chris Barnard Building, Cape Town 7925, South Africa
bResearch Institute for Microbial Diseases, Osaka University, Osaka, Japan
cInstitute of Molecular Medicine, University of California, San Diego, La Jolla, CA, USA
dNational Institute of Health, National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, MD, USA

* Corresponding author. Tel.: +27 21 808 3154; fax: +27 21 808 3145. Email address: rsmith{at}sun.ac.za

Objective: To evaluate the functional requirement of signal transducer and activator of transcription-3 (STAT-3) in cardiac myocyte tolerance to ischemia (I) and in classical preconditioning.

Methods: Cardiac myocyte STAT-3 was depleted in mice using Cre–lox p technology. Isolated cardiomyocytes from wild-type (WT) and STAT-3-deficient mice were evaluated for viability following simulated ischemia (SI; 26 h). Cardiomyocytes were then preconditioned by exposure to transient simulated ischemia or via the administration of preconditioning mimetics (100 µM adenosine, 100 µM diazoxide and 0.5 ng ml–1 TNF{alpha}, individually and in combination) prior to index ischemia. To evaluate the effect of cardiac myocyte depletion of STAT-3 in the context of the intact heart, these experiments were performed in isolated perfused Langendorff heart preparations which were exposed to an index insult of 30-min global ischemia and 45-min reperfusion. Ischemic preconditioning was achieved by subjecting the hearts to four cycles of 5-min ischemia followed by 5-min reperfusion prior to index ischemia. Infarct size was measured following reperfusion.

Results: Cell viability was diminished equally in wild-type and STAT-3-depleted cardiomyocytes. In contrast, ischemic and pharmacological preconditioning protected wild-type cardiomyocytes but not STAT-3-deficient cardiomyocytes. These results were mirrored in the intact heart.

Conclusion: The depletion of functional STAT-3 does not modulate tolerance to ischemic injury in cardiomyocytes. This signaling molecule, however, is crucial for the ischemic and all the tested pharmacological preconditioning programs.

KEYWORDS Ischemia; Preconditioning; Signal transduction


1 From 1st July 2004, Department of Physiological Sciences, University of Stellenbosch, Private Bag X1, Matieland, 7602 South Africa. Tel.: +27 21 808 3146; fax: +27 21 808 3145.

Time for primary review 5 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
K. Boengler, R. Schulz, and G. Heusch
Loss of cardioprotection with ageing
Cardiovasc Res, July 15, 2009; 83(2): 247 - 261.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A. Frias, R. W. James, C. Gerber-Wicht, and U. Lang
Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate
Cardiovasc Res, May 1, 2009; 82(2): 313 - 323.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang
The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis
Cardiovasc Res, October 1, 2008; 80(1): 69 - 77.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Suleman, S. Somers, R. Smith, L. H. Opie, and S. C. Lecour
Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning
Cardiovasc Res, July 1, 2008; 79(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Higuchi, K. Yamauchi-Takihara, G. Matsumiya, N. Fukushima, H. Ichikawa, T. Kuratani, Y. Maehata, and Y. Sawa
Granulocyte Colony-Stimulating Factor Prevents Reperfusion Injury After Heart Preservation
Ann. Thorac. Surg., April 1, 2008; 85(4): 1367 - 1373.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.